Search Medical Condition
Please enter condition
Please choose location from dropdown

Ciudad Autonoma Buenos Aires, Argentina Clinical Trials

A listing of Ciudad Autonoma Buenos Aires, Argentina clinical trials actively recruiting patients volunteers.

RESULTS

Found (311) clinical trials

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

Children are placed into 1 of 4 treatment groups based on age: Group 1, 3 months to 24 months; Group 2, 25 months to 6 years; Group 3, 7 years to 12 years; Group 4, 13 years to 17 years. They receive baseline evaluations. Antiretroviral-naive patients receive emtricitabine plus stavudine ...

Phase

0.0 miles

Learn More »

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Pregnant women experience unique physiological changes that may result in clinically significant alterations in drug PKs. Unfortunately, there have been few clinical trials to study the PKs of ARV, TB, and hormonal contraceptive drugs in pregnant women. The development of appropriate dosing regimens for the HIV-infected pregnant woman is critical ...

Phase

0.0 miles

Learn More »

Phase III Efficacy Safety and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maintenance therapy to prevent relapse (Epoch 1) and GAMMAGARD LIQUID/KIOVIG (immunoglobulin G intravenous (IGIV) 10% administered intravenously) for ...

Phase

0.0 miles

Learn More »

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

A randomized double-blind controlled clinical trial investigating the role of benznidazole in patients with chronic Chagas' heart disease. Chagas disease has 3 phases: acute, undetermined and chronic phases. There are no clinical trials up to date that have investigated the use of antiparasitic drugs in patients that are in the ...

Phase

0.0 miles

Learn More »

Dominantly Inherited Alzheimer Network (DIAN)

Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested: First, that there is ...

Phase N/A

0.0 miles

Learn More »

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored study and who are benefiting from treatment with pasireotide alone or in combination with another treatment for Cushing's Disease and Acromegaly . Eligible patients are to be ...

Phase

0.0 miles

Learn More »

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.

Phase

0.0 miles

Learn More »

This study will enable patients receiving sorafenib (Nexavar) in the completed Bayer/Onyx sponsored clinical trials to continue treatment. During the entire course of the study, numerous patients will be treated with sorafenib. Involvement in this study will be depending on whether the patient benefits from the treatment or not, based ...

Phase

0.0 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 15 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of Tysabri with marketed use, and the impact of treatment ...

Phase N/A

0.0 miles

Learn More »